Mumbai, Aug. 29 -- Goldman Sachs-backed Aragen Life Sciences Ltd is stepping up expansion across biologics and high-potency therapeutics while preparing for an eventual public listing, its top executive toldMint.

The Hyderabad-based contract research, development and manufacturing organization (CRDMO) raised $100 million from Quadria Capital in January 2025, valuing the company at roughly $1.4 billion ( Rs.12,259 crore). The Avendus Future Leaders Fund and SBI Life Insurance also contributed Rs.300 crore in a secondary stake purchase.

An initial public offering (IPO) will likely be the next step for the company, but it wants to time it right, said chief executive officer (CEO) Manni Kantipudi. "...we would like to be one of the largest ...